Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
36.69
+0.28 (0.77%)
At close: Mar 2, 2026, 4:00 PM EST
36.41
-0.28 (-0.75%)
After-hours: Mar 2, 2026, 7:21 PM EST
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Stoke Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $36.1, which forecasts a -1.61% decrease in the stock price over the next year. The lowest target is $25 and the highest is $50.
Price Target: $36.1 (-1.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 7 | 8 | 7 |
| Buy | 2 | 2 | 2 | 1 | 1 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $40 | Buy | Initiates | $40 | +9.02% | Feb 24, 2026 |
| Wedbush | Wedbush | Buy Maintains $32 → $36 | Buy | Maintains | $32 → $36 | -1.88% | Jan 12, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 → $35 | Strong Buy | Maintains | $24 → $35 | -4.61% | Jan 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $28 → $36 | Strong Buy | Maintains | $28 → $36 | -1.88% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 → $50 | Strong Buy | Maintains | $35 → $50 | +36.28% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
193.81M
from 36.56M
Increased by 430.19%
Revenue Next Year
36.27M
from 193.81M
Decreased by -81.29%
EPS This Year
0.20
from -1.65
EPS Next Year
-3.12
from 0.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 209.7M | 73.5M | ||||
| Avg | 193.8M | 36.3M | ||||
| Low | 181.0M | 11.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 473.6% | -62.1% | ||||
| Avg | 430.2% | -81.3% | ||||
| Low | 395.2% | -93.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.45 | -2.42 | ||||
| Avg | 0.20 | -3.12 | ||||
| Low | 0.03 | -3.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.